LH & FSH release
GnRH stimulates pituitary release of the gonadotropins that control ovarian and testicular function.
Explore the research →REPRODUCTIVE HORMONE SIGNALLING
Gonadorelin
A synthetic form of GnRH that activates LH and FSH signalling, with established reproductive biology and clinical research in selected fertility disorders.
LH & FSHOvulationFertility
Established physiology with human fertility evidence in defined settingsPulsatile GnRH can restore reproductive signalling in selected people with hypothalamic GnRH deficiency. That evidence does not translate to generic hormone optimisation.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in Gonadorelin?
Gonadorelin acts at the top of the reproductive hormone pathway, telling the pituitary to release LH and FSH. That makes its role unusually direct: in the right clinical setting it can restore the hormone pulses needed for ovulation and fertility.
Ovulation & fertility
Pulsatile GnRH has induced ovulation and pregnancy in women with hypothalamic amenorrhoea.
Explore the research →Male reproductive signalling
GnRH replacement can be relevant in selected men with hypogonadotropic hypogonadism who want fertility.
Explore the research →Hormone-axis restoration
The appeal is restoration of a missing upstream signal rather than simply raising one downstream hormone.
Explore the research →THE SCIENCE BIT
The pulse at the start of a hormone cascade.
Gonadorelin is synthetic GnRH. It activates GnRH receptors on the pituitary, prompting LH and FSH release and downstream reproductive-hormone activity.
Pattern matters: natural GnRH arrives in pulses. Pulsatile specialist treatment and continuous exposure can produce very different responses, so this is not simply a 'more signal means more hormones' system.
See the studies & trials →- GnRH receptor
- Pituitary target
- LH / FSH
- Downstream hormone release
- Pulses
- The delivery pattern matters
How this connects to the research
Established physiology and selected specialist clinical uses.
FROM MOLECULE TO TISSUE
Where Gonadorelin connects with the body
These are the tissues and biological systems behind the interest in Gonadorelin.
- Pituitary
- Responds to GnRH.
- Ovaries and testes
- Downstream reproductive activity.
- Hypothalamic axis
- The normal hormone rhythm.
The research behind the interest
LH & FSH release
GnRH stimulates pituitary release of the gonadotropins that control ovarian and testicular function.
The effect depends strongly on timing: physiological pulsatile exposure and continuous exposure can produce very different responses.
Established human physiologyExplore the studies →Ovulation & fertility
Pulsatile GnRH has induced ovulation and pregnancy in women with hypothalamic amenorrhoea.
This is a defined medical use requiring diagnosis and monitoring.
Human clinical evidenceExplore the studies →Male reproductive signalling
GnRH replacement can be relevant in selected men with hypogonadotropic hypogonadism who want fertility.
It is not interchangeable with testosterone therapy and requires specialist endocrine care.
Clinical endocrine evidenceExplore the studies →Hormone-axis restoration
The appeal is restoration of a missing upstream signal rather than simply raising one downstream hormone.
That distinction is why diagnosis and pulse pattern matter so much.
Established physiologyExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableOvulation induction with pulsatile GnRH in hypothalamic amenorrhoea ↗
12 women with hypothalamic amenorrhoea
Intravenous or subcutaneous pump
Ovulation was documented in all patients.
The programme produced pregnancies across diagnostic subgroups.
GnRH therapy in hypothalamic primary amenorrhoea ↗
Women with hypothalamic amenorrhoea
Pulsatile GnRH induced ovulation and pregnancy in the reported cohort.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceExtensive
5/5 evidence depth
Extensive human endocrine and fertility literature exists.
✓
Clinical efficacyStrong
4/5 evidence depth
Pulsatile GnRH is effective in selected hypothalamic reproductive disorders.
◇
Safety evidenceStrong
4/5 evidence depth
Safety is best characterised in supervised diagnostic/fertility settings.
⌁
Preclinical evidenceStrong
4/5 evidence depth
Mechanism and reproductive physiology are well established.
HOW TO READ THESE SCORESStrong preclinical evidence · extensive human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
Gonadorelin research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01LH & FSH
RESEARCH AREA 02Ovulation
RESEARCH AREA 03Fertility
RESEARCH AREA 04Reproductive hormones
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Gonadorelin
Interest is mainly around fertility, LH/FSH signalling and preserving reproductive function.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Supporting reproductive hormone output
People are interested in stimulating their own LH and FSH rather than directly supplying downstream hormones. The key insight is that reproductive signalling depends on the pattern of stimulation.
- What makes a report informative
- Measured LH, FSH and downstream hormones in context.
- What can muddy the picture
- Intermittent commercial use is not equivalent to specialist pulsatile GnRH treatment.
Fertility-related use
Interest includes ovulation, sperm production and restoration of reproductive function. These are distinct clinical endpoints rather than consequences that can be assumed from one hormone rise.
- What makes a report informative
- The actual fertility endpoint and specialist diagnosis.
- What can muddy the picture
- Baseline endocrine function and treatment pattern materially alter the response.
Testicular function during hormone treatment
Community interest can involve maintaining testicular function alongside other hormones. Accounts need to identify that background treatment because it changes the entire endocrine context.
- What makes a report informative
- The full hormone regimen and measured outcomes.
- What can muddy the picture
- A subjective change in testicular size does not establish fertility preservation.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
LH & FSH release
The effect depends strongly on timing: physiological pulsatile exposure and continuous exposure can produce very different responses.
Evidence context: Established human physiology
Ovulation & fertility
This is a defined medical use requiring diagnosis and monitoring.
Evidence context: Human clinical evidence
Male reproductive signalling
It is not interchangeable with testosterone therapy and requires specialist endocrine care.
Evidence context: Clinical endocrine evidence
Hormone-axis restoration
That distinction is why diagnosis and pulse pattern matter so much.
Evidence context: Established physiology
The biological rationale
Gonadorelin is synthetic GnRH. It activates GnRH receptors on the pituitary, prompting LH and FSH release and downstream reproductive-hormone activity.
Pattern matters: natural GnRH arrives in pulses. Pulsatile specialist treatment and continuous exposure can produce very different responses, so this is not simply a 'more signal means more hormones' system.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
Clinical gonadorelin use depends on diagnosis, route and pulse pattern; there is no generic hormone-optimisation schedule.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Pulsatile GnRH treatment guide
Human evidence · specialist pump treatmentClinical fertility protocols deliver repeated pulses through a programmed pump. Two or three weekly injections are not equivalent to that therapy. Record specialist appointments or the supplied schedule; the planner does not operate or replace a pulse pump.
Form and route: Pulsatile intravenous or subcutaneous GnRH delivery
The planner keeps amounts and repeat patterns blank for this compound. Use its formulation guide to record an independently specified schedule.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
Pulse pattern changes the biology
What the current evidence saysGnRH is a powerful reproductive signal. Pulsatile and sustained exposure can have different endocrine effects, so medical context and monitoring are central to its established uses.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
5 sourcesSources used on this profile
Original publicationOvulation induction with pulsatile GnRH in hypothalamic amenorrhoeaJournal / DOI ↗Bibliographic recordOvulation induction with pulsatile GnRH in hypothalamic amenorrhoeaPubMed ↗Bibliographic recordGnRH therapy in hypothalamic primary amenorrhoeaPubMed ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesDrugs@FDA ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine identified for this use
Gonadorelin is presented here for research context. Availability online does not establish medicine quality, safety or efficacy.
MHRA products database ↗No FDA-approved therapeutic product identified for this use
Published research and commercial availability are separate from regulatory approval.
Drugs@FDA ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.